The general manager of Tiansli, a well-known pharmaceutical company, resigned

On November 2nd, tiansli's general manager was replaced on October 29th, Tiansli announced that the board of directors had recently received a written resignation report from Zhu Yonghong, who applied to resign as general manager of the company due to the company's strategic development and organizational team building, and continued to serve as a director of the company after resigning.
, through the Tiansli board of directors nomination, compensation and appraisal committee consideration, the appointment of Su Jing as the new general manager.
Public information shows that Su Jing was a basic surgeon at Beijing Concord Hospital, also worked as a sales promotion manager in the northern district of Merca East (China) Co., Ltd., and joined Tianshili in 2003, where she served as general manager, rotating general manager of the marketing group's market planning department, deputy general manager and executive vice president of Tianshili.
, Su Jing is the current director and general manager of Tiansli, and also serves as director and general manager of Tianjin Tiansli Pharmaceutical Commercial Co., Ltd.
from the new general manager who has been involved in marketing for many years, Zhu Yonghong, the former general manager of Tiansli, comes from the field of research and development and production. according to
data, Zhu Yonghong is a Ph.D. in Traditional Chinese Medicine, a registered practicing pharmacist, and also enjoys special allowances from the State Council, and he was an assistant chairman and vice president of the Institute of Tianjin Tiansli Group Co., Ltd., vice president and chief executive officer of Tiansli Holding Group Co., Ltd. and vice chairman of Tiansli.
reported that Zhu Yonghong has twice won the "National Science and Technology Progress Award" second prize, in the process of hosting new product research and development, a total of 18 products were approved for listing.
On the appointment of the new general manager, Tian Shili said that Su Jing for many years in the marketing front line, understand the changing trends in the pharmaceutical industry, the future will focus on the market and patient needs, accelerate organizational efficiency, the implementation of customer demand-oriented business strategy.
is true, executives from different professional backgrounds may be able to bring different development dynamics and focus to the enterprise.
Focus on industrial development and improve profitability October 28, Tiansli released the latest third-quarter report, from the data, Tiansli's main performance indicators gradually out of the adverse factors such as the epidemic, the decline narrowed significantly.
first three quarters of this year, Tiansli achieved operating income of 11.39 billion yuan, net profit of 1.1 billion yuan. In the first quarter, first half and first three quarters of
, tianli's pharmaceutical industry revenue fell by -16.5%, -9.64% and -2%, respectively, and the decline of -2% was almost the same as in the same period last year.
Tiansli pointed out in its third-quarter report that sales of cold and fever drugs increased significantly year-on-year, while revenue from cardiovascular and anti-tumor products decreased year-on-year as a result of the outbreak and the implementation of new prices for the three health insurance negotiating varieties.
For some time now, Tiansli has actively divested the commercial plate of medicine, promoted the listing of Tiansli Bio, continued to focus on the development of the pharmaceutical industry, the use of Traditional Chinese medicine, chemical medicine, biological medicine coordinated development characteristics, focusing on cardiovascular, digestive metabolism, anti-tumor three therapeutic areas.
its semi-annual report, Tian Shili said it will continue to steadily promote innovative product development and product structure optimization in the future to ensure sustainable growth in performance.
According to Tiansli's semi-annual report, Tiansli's Chinese medicine pipeline to cardiovascular medicine-based, the main products are compound Dansan drop pills, serum brain particles (pills), ginseng beneficial gas drops, injection of beneficial gas complex veins, injection of dansin polyphenol acid, etc.; Injection recombinant human urine kinase and series follow-up in the research pipeline; chemical drugs, imitation combination, research and development around the field of anti-tumor, cardiovascular, digestive metabolism and spiritual, layout of a number of innovative drugs and generic drugs, has been listed products including anti-tumor drugs, cardiovascular drugs, psychotic drugs and liver protection drugs.
in its previous announcement, Tiansli said it was actively promoting the sale of Tiansi's marketing stake in order to further focus on the development of the pharmaceutical industry, improve its asset structure, enhance profitability, and build an innovative pharmaceutical research and development cluster.
According to the latest related announcement, Tiansli indirectly controlled six partnerships to Chongqing Pharmaceuticals to sell 100% of the shares of Tiansi Marketing, has been completed, the relevant industrial and commercial change registration procedures have been completed, on August 13 this year, Tiansli Marketing has obtained the latest business license.
, Tiansli is also actively promoting the spin-off of Tiansli Bio to the listing of the Science and Trot board.
It is learned that Tiansli Bio has submitted a guidance record to the Shanghai Regulatory Bureau of the CSRC on June 5, 2020, and the Shanghai Regulatory Bureau of the CSRC announced on August 20 that the sponsor agency's "Summary Report on Counseling Work" for Tiansli Bio.
Tian Shili believes that the implementation of the above projects will further enhance its value in the field of innovative drugs, for the follow-up biopharmaceutical innovation research and development to provide a strong financing guarantee, while effectively reducing the asset-liability ratio, improve operating cash flow, improve operating quality and operational efficiency, focus on the company's core strategy, accelerate the construction of innovative pharmaceutical research and development clusters and marketing innovation, and better play the advantages and synergies of multi-product clusters.
Indeed, according to the latest third-quarter report, Tiansli's financial position improved significantly after the sale of the pharmaceutical business: accounts receivable fell sharply, and accounts receivable fell to $2.24 billion in the third quarter from $8.43 billion at the end of 2019.
the debt-to-equity ratio fell sharply, to 26.7% at the end of the third quarter from 50.6% at the end of 2019.
, the price of generic drugs is facing a downtate, driven by supporting policies such as drug collection and collection by the state.
, the relevant departments continue to deal with the problem of inflated drug prices.
with the dynamic adjustment of the medical insurance catalogue and the reform of the payment method of medical insurance, a group of pharmaceutical companies are facing policy pressure at the market end.
addition, new product development risks, API price increase risks, investment mergers and acquisitions risks, subsidiary management risks, etc., for pharmaceutical companies, may also be like a reef to hinder their development.
effective control of risk and enterprise development costs, and timely seize the opportunity to improve market returns, is the need for a group of pharmaceutical companies to think about the problem.